[Answered] Oceanic upwelling is caused by density differences in the water mass. Indicate whether the statement ...

This topic contains a solution. Click here to go to the answer

Author Question: Oceanic upwelling is caused by density differences in the water mass. Indicate whether the statement ... (Read 14 times)

Diane

Hero Member
Posts: 576

on: Jul 15, 2018

Oceanic upwelling is caused by density differences in the water mass. Indicate whether the statement is true or false.

Question 2

Sahel is the name given to a certain kind of desert ravine. Indicate whether the statement is true or false.

Need homework help now?

Ask unlimited questions for free

Ask a Question

Marked as best answer by a Subject Expert

Laurenleakan

Sr. Member
Posts: 309

Reply #1 on: Jul 15, 2018

Answer to Question 1

F

Answer to Question 2

F

Diane

Member
Posts: 576

Reply 2 on: Jul 15, 2018

Thanks for the timely response, appreciate it

LegendaryAnswers

Member
Posts: 341

Reply 3 on: Yesterday

Great answer, keep it coming

« previous next »

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

According to the National Institute of Environmental Health Sciences, lung disease is the third leading killer in the United States, responsible for one in seven deaths. It is the leading cause of death among infants under the age of one year.

Did you know?

To prove that stomach ulcers were caused by bacteria and not by stress, a researcher consumed an entire laboratory beaker full of bacterial culture. After this, he did indeed develop stomach ulcers, and won the Nobel Prize for his discovery.

Did you know?

Many supplement containers do not even contain what their labels say. There are many documented reports of products containing much less, or more, that what is listed on their labels. They may also contain undisclosed prescription drugs and even contaminants.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.